Cetuximab, an IgG1 monoclonal antibodies, can bind with EGFR protein of tumor cell by its Fab fragment, and its Fc fragment engages FCGR on an immune cell to activate the process of ADCC, eventually resulting in attacking and eliminating the cetuximab-coated tumor cell. This evidence concerns the gene EGFR and neoplasm.